BioSpace News Archive

Rx-360 released the fourth episode of The Patient Safety Podcast, featuring an interview with Leigh Verbois, the Director of the Office of Drug Security, Integrity, and Response for the FDA

ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference.

HydroCision Inc. announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,278,305, titled “Selective Tissue Removal Treatment Device,” for their TenJet device.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022.

Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.

MiMedx Group, Inc. announced that, based on the preliminary vote count provided by its proxy solicitor, shareholders have approved all proposals set forth by the Company at the 2022 Annual Meeting of Shareholders, including the reelection of both of MIMEDX’s directors, Dr. Phyllis Gardner and James L. Bierman, and the proposals on say-on-pay and the Company’s qualified employee stock purchase plan.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease.

Eiger BioPharmaceuticals, Inc. announced that it has entered into a term loan agreement with an affiliate of Innovatus Capital Partners, LLC for up to $75 million and a stock purchase agreement for Innovatus to purchase $5 million of the Company’s stock.

Nyxoah SA is proud to announce that it is part of the newly-formed Euronext Tech Leaders initiative, which is composed of 100+ innovative and high-growth technology companies with greater than 1 trillion Euros in aggregate market capitalization.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that its pivotal Phase 3 trial EPITOPE (EPIT in TOddlers with PEanut Allergy), assessing the safety and efficacy of Viaskin™ Peanut 250 µg for the treatment of peanut-allergic toddlers ages 1 to 3 years, met its primary endpoint.